Pliant Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Redwood City CA United States (2015)

Organization Overview

First Clinical Trial
2017
NCT03183570
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Pliant Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

Bexotegrast (6 trials)

Drugs in Phase 1 Trials (1)

18f fp-r01-mg-f2 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Cholangitis (Phase 2)

Cholangitis, Sclerosing (Phase 2)

Fibrosis (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 2)

Pulmonary Fibrosis (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 2